Edwards Historical Cash Flow
| EW Stock | USD 72.37 0.41 0.57% |
Analysis of Edwards Lifesciences cash flow over time is an excellent tool to project Edwards Lifesciences Corp future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 175 M or Other Non Cash Items of 6.4 M as it is a great indicator of Edwards Lifesciences ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Edwards Lifesciences Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Edwards Lifesciences Corp is a good buy for the upcoming year.
Edwards |
About Edwards Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Edwards balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Edwards's non-liquid assets can be easily converted into cash.
Edwards Lifesciences Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Capital Expenditures
Capital Expenditures are funds used by Edwards Lifesciences Corp to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Edwards Lifesciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Edwards Lifesciences Corp financial statement analysis. It represents the amount of money remaining after all of Edwards Lifesciences Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Most accounts from Edwards Lifesciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Edwards Lifesciences Corp current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. At this time, Edwards Lifesciences' Cash Flows Other Operating is fairly stable compared to the past year.
Edwards Lifesciences cash flow statement Correlations
Click cells to compare fundamentals
Edwards Lifesciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Edwards Lifesciences cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (120.6M) | 19M | (213.4M) | (289M) | (260.1M) | (247.1M) | |
| Free Cash Flow | 647M | 1.4B | 953.4M | 629.5M | 723.9M | 444.3M | |
| Change In Working Capital | 42.2M | 145.3M | (421.4M) | (526.3M) | (473.7M) | (450.0M) | |
| Other Cashflows From Financing Activities | 139.3M | 158.3M | 142.8M | 168.9M | 194.2M | 184.5M | |
| Depreciation | 107.2M | 134.8M | 139.6M | 144.9M | 166.6M | 175.0M | |
| Other Non Cash Items | 38.3M | (119M) | 105.8M | 7.5M | 6.8M | 6.4M | |
| Capital Expenditures | 407.3M | 329.8M | 264.8M | 266.3M | 306.2M | 321.6M | |
| Total Cash From Operating Activities | 1.1B | 1.7B | 1.2B | 895.8M | 1.0B | 590.9M | |
| Net Income | 823.4M | 1.5B | 1.5B | 1.4B | 1.6B | 1.7B | |
| Total Cash From Financing Activities | (486.9M) | (356.3M) | (1.6B) | (711M) | (639.9M) | (607.9M) | |
| Change In Cash | 15.8M | (332.8M) | (94.8M) | 375.4M | 431.7M | 453.3M | |
| End Period Cash Flow | 1.2B | 867.4M | 772.6M | 1.1B | 1.3B | 1.4B | |
| Other Cashflows From Investing Activities | (446.4M) | (359.3M) | (63.1M) | (75M) | (67.5M) | (70.9M) | |
| Stock Based Compensation | 92.6M | 109.3M | 126.8M | 139.4M | 160.3M | 168.3M | |
| Begin Period Cash Flow | 1.2B | 1.2B | 867.4M | 772.6M | 888.5M | 499.0M | |
| Change To Liabilities | (20.3M) | (137.4M) | 257.2M | (27M) | (31.1M) | (29.5M) | |
| Sale Purchase Of Stock | (625.4M) | (512.8M) | (1.7B) | (879.6M) | (791.6M) | (752.1M) | |
| Change To Account Receivables | 283.9M | (112.4M) | (84.1M) | (141.2M) | (127.1M) | (120.7M) | |
| Total Cashflows From Investing Activities | (595.8M) | (531.1M) | (1.7B) | 252.3M | 227.1M | 238.4M | |
| Dividends Paid | 140.5M | 158.6M | 146.4M | 169.9M | 152.9M | 233.1M | |
| Investments | (101.7M) | (1.3B) | 252.3M | 254.4M | 292.6M | 307.2M | |
| Change Receivables | (88M) | 41.9M | (91.1M) | (84.1M) | (75.7M) | (71.9M) | |
| Net Borrowings | (10M) | (800K) | (1.8M) | (200K) | (180K) | (171K) | |
| Cash And Cash Equivalents Changes | 468M | 36.3M | (346.7M) | (114M) | (102.6M) | (97.5M) | |
| Cash Flows Other Operating | 1.1B | 1.1B | 1.5B | 1.5B | 1.7B | 1.8B | |
| Change To Netincome | 198.2M | 53.3M | (79.6M) | (49.1M) | (56.5M) | (53.6M) | |
| Change To Operating Activities | 9.4M | 258.3M | (39.8M) | (96.9M) | (87.2M) | (82.8M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Edwards Stock Analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.